{"id":"F2005L02778","name":"National Health Act 1953 - Determination under section 93 (No. PB 28 of 2005)","slug":"national-health-act-1953-determination-under-section-93-no-pb-28-of-2005","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":37667,"registerId":"commonwealth-F2005L02778-current","compilationNumber":null,"startDate":"2026-04-01","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"National Health Act 1953 - Determination under section 93 (No. PB 28 of 2005)","content":"PBS Determination 93COMMONWEALTH OF AUSTRALIA\n\nNational Health Act 1953\n\nPHARMACEUTICAL BENEFITS\n\nDETERMINATION UNDER SECTION 93\n\nNo. PB 28 of 2005\n\nI, JOAN CORBETT, Assistant Secretary, Pharmaceutical Benefits Branch, Department of Health and Ageing and Delegate of the Minister for Health and Ageing, pursuant to section 93 of the National Health Act 1953, hereby make the following Determination:\n\n1. This Determination commences on 1 October 2005.\n2. Determination No. PB 20 of 2005 under section 93 of the National Health Act 1953, made on 26 July 2005 with effect from 1 August 2005, is repealed.\n3. The pharmaceutical benefits referred to in this Determination shall be those specified in the Schedule to this Determination.\n4. A medical practitioner is authorised for the purpose of section 93 of the National Health Act 1953 to supply any of the pharmaceutical benefits obtained by the medical practitioner, or by another medical practitioner for whom the first-named medical practitioner is temporarily acting as a locum, in pursuance of this Determination.\n5. Subject to this Determination, the maximum quantity or number of units of a pharmaceutical benefit which may be obtained by a medical practitioner in any one month for the purpose of section 93 of the National Health Act 1953 is the quantity or number specified in the Schedule to this Determination in relation to the pharmaceutical benefit.\n6. Where a medical practitioner has obtained a pharmaceutical benefit for the purpose of section 93 of the National Health Act 1953, that medical practitioner is not entitled to obtain a further quantity or number of units of that pharmaceutical benefit for that purpose whilst in possession of a quantity or number of units of the pharmaceutical benefit obtained by the medical practitioner equal to or greater than the maximum quantity or number of units allowed for the pharmaceutical benefit by paragraph 5.\n\n \nTHE SCHEDULE\n\n| Name of pharmaceutical benefit | Form (strength, type, size, etc.) | Maximum quantity |\n| ------------------------------ | --------------------------------- | ---------------- |\n\n```html\n

Adrenaline Acid Tartrate

Injection equivalent to adrenaline 1 in 1,000, 1 mL

5

Atropine Sulfate

Injection 600 micrograms in 1 mL ampoule

10

Benztropine Mesylate

Injection 2 mg in 2 mL ampoule

5

Benzylpenicillin Sodium with any determined brand of sterilised Water for Injections

Injection equivalent to 600 mg benzylpenicillin, vial (with 10 mL ampoule)

10

OR

Procaine Penicillin

Injection 1.5 g in disposable syringe

5

Benzylpenicillin Sodium with any determined brand of sterilised Water for Injections

Injection equivalent to 3 g benzylpenicillin, vial (with 10 mL ampoule)

1

Chlorpromazine Hydrochloride

Injection 50 mg in 2 mL ampoule

10

OR

Haloperidol

Injection 5 mg in 1 mL ampoule

10

Dexamethasone Sodium Phosphate

Injection equivalent to 4 mg dexamethasone phosphate in 1 mL ampoule

5

OR

Hydrocortisone Sodium Succinate

Injection equivalent to 100 mg hydrocortisone with 2 mL solvent

2

OR

Hydrocortisone Sodium Succinate

Injection equivalent to 250 mg hydrocortisone with 2 mL solvent

1

Diazepam

Injection 10 mg in 2 mL ampoule

5

Dihydroergotamine Mesylate

Injection 1 mg in 1 mL ampoule

5

Diphtheria and Tetanus Vaccine - Adsorbed (Diluted)

Injection 0.5 mL in pre-filled syringe

15

Frusemide Sodium

Injection equivalent to 20 mg frusemide in 2 mL ampoule

5

Glucagon Hydrochloride

Injection set containing 1 mg (1 I.U.) and 1 mL solvent in disposable syringe

1

Glyceryl Trinitrate

Buccal/sublingual spray (pump pack) 400 micrograms per dose, 200 doses

1

Lignocaine Hydrochloride

Injection 100 mg in 5 mL

5

Metoclopramide Hydrochloride

Injection 10 mg in 2 mL ampoule

10

OR

Prochlorperazine Mesylate

Injection 12.5 mg in 1 mL ampoule

10

Morphine Sulfate

Injection 15 mg in 1 mL ampoule

5

OR

Morphine Sulfate

Injection 30 mg in 1 mL ampoule

5

Naloxone Hydrochloride

Injection 800 micrograms in 2 mL disposable injection set

5

OR

Naloxone Hydrochloride

Injection 2 mg in 5 mL disposable injection set

2

Pethidine Hydrochloride

Injection 100 mg in 2 mL ampoule

5

OR

Tramadol Hydrochloride

Injection 100 mg in 2 mL ampoule

5

Promethazine Hydrochloride

Injection 50 mg in 2 mL ampoule

10

Salbutamol Sulfate

Pressurised inhalation equivalent to 100 micrograms salbutamol per dose, 200 doses (CFC-free formulation)

1

OR

Salbutamol Sulfate

Nebuliser solution equivalent to 2.5 mg salbutamol in 2.5 mL single dose units, 30

1

Salbutamol Sulfate

Nebuliser solution equivalent to 5 mg salbutamol in 2.5 mL single dose units, 30

1

Terbutaline Sulfate

Injection 500 micrograms in 1 mL ampoule

5

Tetanus Vaccine - Adsorbed

Injection 0.5 mL in pre-filled syringe

5

Verapamil Hydrochloride

Injection 5 mg in 2 mL ampoule

5

\n```\n\nDated this sixteenth day of September 2005.\n\n| |\n| ------------------------------------------------------------------------------------------------------------------------------------------ |\n| JOAN CORBETTAssistant SecretaryPharmaceutical Benefits BranchDepartment of Health and AgeingDelegate of the Minister for Health and Ageing |","sortOrder":0}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-realtime","completionTokens":2597},"content_quality":"ok","complexity_score":2,"scope_assessment":{"changed":false,"description":"This is a routine administrative update that repeals and replaces Determination No. PB 20 of 2005. It maintains the established scope of section 93 of the National Health Act 1953, which governs pharmaceutical benefits supplied directly by medical practitioners. The instrument does not expand beyond the original legislative purpose of regulating emergency medications kept by doctors for immediate patient treatment."},"complexity_factors":["Simple delegated instrument with only 6 operative clauses","Single schedule containing a table of approximately 30 pharmaceutical items with straightforward quantity limits","Basic conditional rule (no restocking while holding maximum quantity) without nested exceptions","Minimal cross-referencing limited to the parent Act (section 93 of the National Health Act 1953)"],"plain_english_summary":"This instrument authorises medical practitioners under the PBS to supply listed emergency and essential medicines directly to patients—so doctors can hand over life‑saving drugs (eg adrenaline, naloxone, morphine, inhalers) for immediate care rather than issuing a prescription. \n\nIt imposes monthly quantity limits, prevents ordering beyond those limits to deter stockpiling, and allows locum doctors to supply on behalf of the regular practitioner, ensuring rapid, subsidised access in emergencies."}},"importantCases":[],"_links":{"self":"/api/acts/national-health-act-1953-determination-under-section-93-no-pb-28-of-2005","history":"/api/acts/national-health-act-1953-determination-under-section-93-no-pb-28-of-2005/history","analysis":"/api/acts/national-health-act-1953-determination-under-section-93-no-pb-28-of-2005/analysis","conflicts":"/api/acts/national-health-act-1953-determination-under-section-93-no-pb-28-of-2005/conflicts","importantCases":"/api/acts/national-health-act-1953-determination-under-section-93-no-pb-28-of-2005/important-cases","documents":"/api/acts/national-health-act-1953-determination-under-section-93-no-pb-28-of-2005/documents"}}